Background: Although several studies have explored the genetic polymorphisms of apolipoprotein E (APOE) and their impact on premature coronary artery disease (PCAD), there is still some controversy regarding the significance of their association. Our aim is to estimate the association between APOE polymorphisms and PCAD via meta-analysis. Methods: All relevant case-control studies and cohort studies published in Chinese or English prior to March 2016 were searched for in electronic databases. Detailed information concerning each piece of literature was independently extracted by two researchers. We used STATA11.0 to process all data and to determine the pooled odds ratio (OR). Altogether, four genetic models were applied to calculate OR and 95% confidence interval (CI): (1) ε2 allele vs. ε3 allele; (2) ε2 carriers vs. ε3/3; (3) ε4 allele vs. ε3 allele; (4) ε4 carriers vs. ε3/3. Results: Eighteen studies concerning APOE polymorphisms and their impact on PCAD were included in the final analysis. The pooled analysis displayed that the ε2 allele and ε2 carriers increased the risk of PCAD significantly among Asians (OR 1.54; 95% CI, 1.09-2.17; OR 1.65;
Introduction
Coronary artery disease (CAD), a multifactorial heart disorder resulting from all kinds of predisposing environmental and genetic factors [1] , is still one of the leading causes of disability and death around the world, accounting for 14.8% of global death [2] . Premature coronary artery disease (PCAD) is defined as CAD that occurs in males < 55 years old or females < 65 years old [3] . Even though PCAD constitutes only about 30% of all CAD subjects [4, 5] , it is highly stressful for the patients' families and generates a heavy social burden because of the longer period that the patient lives with the disease in comparison to older patients with CAD [6] . Large epidemiological studies have revealed that genetic factors have a strong influence on early onset CAD [7] . One known factor is the apolipoprotein E (APOE) gene [8] .
Apolipoprotein E (apoE) is a multifunction glycoprotein containing 299 amino acids, which are encoded by the APOE gene [9] . It acts as cholesterol carrier and plays a major role in mediating the transportation and metabolism of lipids [10] . The APOE gene is situated at 19q13.2 of the human chromosome and has four exons and three introns [11] . As the genetic polymorphisms which are most widely studied in APOE, rs429358 and rs7412 together define the ε2, ε3, and ε4 alleles, which encode three major protein isoforms (E2, E3, E4) and generate six different genotypes (ε2/4, ε2/3, ε3/4, ε3/3, ε2/2, ε4/4) [12] . There is significant discrepancy in structure and function among the three protein isoforms [12] . ε3 is the wild type, and its amino acids at positions 112 and 158 are cysteine and arginine, respectively [10] . It has normal affinity for low-density lipoprotein receptors (LDLR) and modulates the clearance of lipoprotein remnants from the plasma [12] . When the 112th amino acid is replaced by arginine, ε3 mutates into ε4. Similarly, ε3 mutates into ε2 when the 158th amino acid is replaced by cysteine [13] . ε4 has similar high affinity for LDLR as ε3 and enhanced binding capacity for lipids, so it impairs the process of lipolysis and is associated with high levels of very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and total cholesterol [12] . As for ε2, it has defective affinity ability for LDLR, which would delay the clearance of VLDL. ε2 is associated with low levels of LDL and total cholesterol [12] .
Several meta-analyses have been conducted to explore the impact of APOE polymorphisms on CAD. The analysis conducted by Hong Xu found that the ε2 allele in APOE decreased the prevalence of myocardial infarction while the ε4 allele increased the incidence [14] . Two other meta-analyses conducted in the Chinese population also found a high risk of the ε4 allele for CAD [15, 16] . However, no meta-analysis explored the genetic risk of APOE in PCAD. Due to strong evidence that genetic factors have an influence on PCAD and that APOE ε4 has an indirect impact on CAD [17] , examining the impact of APOE polymorphisms on PCAD could eliminate possible confounding factors which are related to advanced age and could allow for more precise evaluation of the risk of inherited mutations. Although several studies have explored the genetic polymorphisms of APOE and their impact on PCAD [8, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , the significance of their association is yet to be determined. Our aim is to estimate the association between APOE polymorphisms and PCAD by conducting this meta-analysis.
Materials and methods

Search strategy
All relevant case control studies and cohort studies exploring APOE polymorphisms and their relationship with PCAD published in Chinese or English prior to March 28th, 2016 were searched for in electronic databases, including PubMed, Embase, Web of Science, Wanfang Database, Chinese National Knowledge Infrastructure, VIP Database, and China Biological Medicine using all feasible combinations of the following key words: ('CAD' OR 'coronary heart disease' OR 'ischemic heart disease' OR 'myocardial infarction' OR 'angina pectoris' OR 'acute heart failure' OR 'cardiovascular disease') AND ('gene polymorphisms' OR 'allele' OR 'genotype' OR 'single nucleotide polymorphism') AND ('apolipoprotein E' OR 'apoE') AND ('premature' OR 'young'). The references of all retrieved literature were also screened. In case of duplicated data in publications studying the same group of people, we kept the more recent publication or the one that had the greatest sample size.
Inclusion and exclusion criteria
To identify all eligible publications, the inclusion criteria were listed as follows: (1) studies explored APOE polymorphisms and their association with PCAD; (2) case control studies or cohort studies; (3) case groups needed to be clearly diagnosed with PCAD, which was defined as CAD that occurs in males < 55 or females < 65 [3] ; (4) control groups should be without CAD; (5) the distribution of both sample sizes and alleles should be reported in the studies; and (6) the study is of high quality.
The exclusion criteria listed as follows were used: (1) reviews; (2) case reports; (3) letters; and (4) duplicated researches.
Data extraction
Two authors independently screened the literature to minimize selection bias. For potential relevant literature whose full-texts could not be acquired online, emails were sent to corresponding authors to obtain full text. Detailed information concerning each piece of eligible literature was extracted by two researchers independently. Information included first author's name, year of publication, ethnicity, clinical subtype, source of control, male percentage, mean age, mean BMI, sample size of controls and cases, genotyping method, HardyWeinberg equilibrium (HWE), the distribution of genotypes and frequencies of allele in cases and controls. Any disputes were settled by a third researcher.
Quality assessment of included studies
The quality of all eligible publications was assessed by two authors based on the Newcastle-Ottawa assessment scale [35] . Asterisks (*) were used as quality indicators, and better quality studies would be awarded more stars for a maximum of up to nine stars. Studies with more than six stars were perceived as high quality. Moreover, two authors assessed the risk of bias in each literature based on the Quality In Prognosis Studies (QUIPS) tool [36] , which contains six bias domains. The bias of each domain is rated as having high, moderate, or low risk of bias. Any disputes were settled by a third researcher.
Statistical analysis
We applied pooled odds ratio (OR) and its corresponding 95% CI to assess the intensity of the influence of APOE polymorphisms on PCAD, and Z test was used to examine the statistical significance of the OR. As ε3/3 is the most common genotype among humans [37] , we designated the ε3 allele or genotype ε3/3 as the reference category in our meta-analysis. Genotypes ε2/2 and ε4/4 were detected in only a few studies. Altogether, four genetic models were applied to calculate OR and 95% CI: (1) ε2 allele vs. ε3 allele; (2) ε2 carriers vs. ε3/3; (3) ε4 allele vs. ε3 allele; (4) ε4 carriers vs. ε3/3. (Patients with genotypes ε2/3 and ε2/2 were included in ε2 carriers. Similarly, patients with genotypes ε4/3 and ε4/4 were included in ε4 carriers) [16] . The distribution of genotypes was examined by χ 2 -test to test if it fulfilled the HWE criteria. We used the I 2 test to examine the heterogeneity among all publications (I 2 <25%, low heterogeneity; 25% ≤ I 2 <50%, moderate heterogeneity; I 2 ≥ 50%, high heterogeneity) [38] . For publications with moderate or high heterogeneity, we chose random effects models to merge OR; otherwise, fixed effects models were selected. Different features concerning studied populations resulted in discrepancies in results, thus we conducted stratified analyses by ethnicity (Caucasian, Asian, or African), clinical subtype (CAD or MI), source of control [population based (PB) or hospital based (HB)], male percentage ( ≥ 65% or < 65%), and sample size ( ≥ 250 or < 250). Furthermore, we utilized univariate meta-regression analyses to identify the source of heterogeneity among studies and investigate the effects of different moderators (ethnicity, mean age, HWE, source of control, clinical subtype, male percentage, and mean BMI). Sensitivity analysis was conducted to test the stabilization of the results by omitting each research. Begg's test [39] and Egger's test [40] were performed to detect the publication bias. All the data were processed by STATA11.0 for windows (Stata, College Station, TX, USA). A p-value < 0.05 indicated statistically significant.
Results
Study characteristics
The detailed screening process for all relevant literature is displayed in a flow diagram shown in Figure 1 . Initially, 472 relevant publications were identified, while only 18 research reports covering a total of 2361 PCAD and 2811 controls fulfilled the inclusion criteria and were included in our analysis. Detailed information concerning each piece of eligible publication was listed in Table 1 . The distribution of genotypes and frequencies of APOE allele is shown in Table 2 . Results of quality assessment based on the NewcastleOttawa assessment scale are displayed in Table 3 , while the results of risk of bias assessment are shown in Table 4 .
Association between ε2 allele and PCAD
The results of the ε2 allele and its carriers are shown in Figures 2 and 3. We chose random effects models to merge all data based on its moderate heterogeneity (for ε2 allele vs. Table 5 .
Association between ε4 allele and PCAD
Due to the heterogeneity among studies exploring the associations between the ε4 allele and ε4 carriers with Table 5 . Forest plots of subgroup analyses by ethnicity were displayed in Figure 7 .
Meta-regression
Univariate meta-regression analyses revealed that ethnicity accounted for 55.2% of the between-study heterogeneity for the ε2 allele vs. ε3 allele model (adjusted R 2 = 63.47%, p = 0.05), 100% of the between-study heterogeneity for the ε2 carriers vs. ε3/3 model (adjusted R 2 = 100%, p = 0.00), 28.6% of the between-study heterogeneity for the ε4 allele vs. ε3 allele model (adjusted R 2 = 40.55%, p = 0.02), and 24.0% of the between-study heterogeneity for the ε4 carriers vs. for the ε2 allele vs. ε3 allele model, while the other factors did not show significant results, which suggested that ethnicity was the main source of heterogeneity. Detailed results of meta-regression analyses were listed in Table 6 .
Sensitivity analysis
Sensitivity analyses showed that the overall calculated OR did not change significantly after excluding each literature, which confirmed the stability and reliability of our analysis.
Publication bias
No obvious asymmetry appeared in funnel plots shown in Figure 8 . At the same time, Begg's correlation (ε2 vs. ε3: p = 1.00; ε2 carriers vs. ε3/3: p = 0.97; ε4 vs. ε3: p = 0.23; ε4 carriers vs. ε3/3: p = 0.17) and Egger's regression (ε2 vs. ε3: p = 0.75; ε2 carriers vs. ε3/3: p = 0.97; ε4 vs. ε3: p = 0.06; ε4 carriers vs. ε3/3: p = 0.05) did not reveal any obvious publication bias among our eligible publications. 
Discussion
Although several recent meta-analyses explored the genetic risk of APOE polymorphisms in CAD [14] [15] [16] , our analysis was the first comprehensive assessment in PCAD.
Merging the data of all eligible publications revealed that subjects with the ε4 allele conferred 62% more predisposition to PCAD, while ε4 carriers had 65% higher risk for PCAD. People with the ε2 allele and ε2 carriers showed moderately protective effects on PCAD when merging all data. The results indicated that mutation of ε3-ε4 in APOE may be a genetic risk factor for PCAD. Meta-regression analyses showed that ethnicity could explain most of the heterogeneity among studies exploring the associations between the ε2 allele or ε2 carriers and PCAD. Increased risk for PCAD was found in Asians with the ε2 allele, and we proposed that the ε2 allele may be a genetic risk factor for PCAD in Asians. This was in contrast to the decreased susceptibility of PCAD occurring in Caucasian subjects with the ε2 allele or ε2 carriers, which provided evidence that the ε2 allele was a genetic protective factor for PCAD in Caucasians.
It was assumed that the association between the ε2 allele and type III hyperlipoproteinemia which is associated with PCAD [41] , contributed to this geographical variability. Instead of high prevalence of the ε2/2 genotype in type III hyperlipoproteinemia seen in most other geographical areas, Asians are characterized by high prevalence of ε2/3 and ε2/2 genotypes [42, 43] , which may be responsible for the genetic risk of the ε2 allele for PCAD in Asians. As the number of ε2/2 genotype in the population is very low, the ε2 allele could still act as a protective factor for Caucasians based on its association with low levels of LDL. Besides, differences in dietary habits exist between Caucasians and Asians [44] , which could partially explain this discrepancy. Limited by the relatively small sample size of Asians in the included literature, further larger sample studies are still needed to confirm this result. As for the ε4 allele and ε4 carriers, Asian people showed much higher risk for PCAD compared with Caucasians, which may due to the differences in dietary habits between Caucasians and Asians [44] . When categorized by source of control, the ε2 allele and ε2 carriers showed significant associations with PCAD in population-based studies while no significant associations were found in hospital-based studies. Controls from hospital-based cases may have had diseases associated with APOE polymorphisms, which would confound the impact of APOE polymorphisms on PCAD and which may have been responsible for this discrepancy. In subgroup analysis by male percentage, the four models showed significant association with PCAD in studies where males percentage were ≥ 65%, while only ε2 carriers showed significant effects in the males percentage < 65% subgroup. A number of epidemiological investigations indicated that lifestyle factors, such as tobacco smoking, alcohol consumption, and physical activity, could interact with the APOE gene to influence plasma lipid concentration [45, 46] . Compared to men, the proportion of smokers or drinkers is relative lower in females. Thus, the effect of APOE polymorphisms on PCAD may display discrepancy in sex. When stratified by sample size, no significant associations were found in the ε2 allele and ε2 carriers in sample sizes < 250 or ≥ 250, indicating that heterogeneity did not originate from sample size. Even though possession of the ε4 allele was associated with elevated risk of PCAD in both overall and subgroup analyses, heterogeneity among studies remained high.
The mechanisms for the influence of APOE polymorphisms on PCAD are partially understood. A number of studies investigated the associations of APOE polymorphisms with lipid level [47] , metabolic syndrome [48] , and arteriostenosis [49] . Evidence suggested that apoE participated in the metabolism of lipids in the liver, and different isoforms of apoE differed in affinity to corresponding receptors and performed different functions [50] . E4 is associated with high levels of LDL, total cholesterol and risk of carotid artery stenosis, while E2 is associated with reduction of LDL and total cholesterol [17] . Thus, APOE polymorphisms affect the prevalence of PCAD indirectly through mediating the concentration of plasma lipid. Additionally, ε4 in APOE has an intimate association with increased apoB and is known as a risk factor for hypertension [51] , which may be a contributing factor to its negative effect on PCAD.
From the results, we confirmed that people with the ε4 allele are at high risk of PCAD and need to be detected early and to receive appropriate counseling in case contracting PCAD. Asians with the ε2 allele need to be paid more attention as well. 
Limitations
Although the obvious effect of APOE on PCAD was detected, several limitations remind us to interpret the results with caution. Firstly, several authors did not respond to our request to obtain original data, which could affect the integrity of the information included, so we did not include their studies in our meta-analysis. Secondly, the heterogeneity among studies exploring the association between the ε4 allele or ε4 carriers and PCAD remained a very high level even though we applied subgroup analysis. The last, the number of ε2/2 is too low in our research.
Conclusions
In conclusion, our study described the distribution of APOE polymorphisms in PCAD and detected that the ε2 allele appeared as a risk factor for PCAD in Asians while remaining a protective factor in Caucasians, and confirmed that the ε4 allele in APOE was associated with a high risk for PCAD in general. Furthermore, larger sample investigations of different subgroups are still needed to obtain a more definite conclusion.
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